Assessment of new anti-HER2 ligands using combined docking, QM/MM scoring and MD simulation

Ahmed, Marawan; Sadek, Maiada M; Serya, Rabah; Kafafy, Abdel-Hamid N; Wang, Feng; Khaled A M Abouzid;

Abstract


In the development of new anti-cancer drugs to tackle the problem of resistance to current chemotherapeutic agents, a new series of anti-HER2 (human epidermal growth factor receptors 2) agents has been synthesized and investigated using different computational methods. Although non-selective, the most active inhibitor in the new series shows higher activity toward HER2 than EGFR. The induced fit docking protocol (IFD) is performed to find possible binding poses of the new inhibitors in the active site of the HER2 receptor. Molecular dynamic simulations of the inhibitor-protein complexes for the two most active compounds from the new series are carried out. Simulations stability is checked using different stability parameters. Different scoring functions are employed.


Other data

Title Assessment of new anti-HER2 ligands using combined docking, QM/MM scoring and MD simulation
Authors Ahmed, Marawan; Sadek, Maiada M; Serya, Rabah ; Kafafy, Abdel-Hamid N; Wang, Feng; Khaled A M Abouzid 
Keywords Protein kinase; HER2; Molecular dynamics; AMBER; QM/MM scoring; MOLECULAR-DYNAMICS; MULTIDRUG-RESISTANCE; KINASE INHIBITORS; FORCE-FIELD; PROTEIN; MODEL; PREDICTION; COMPLEXES; MECHANISM; CANCER
Issue Date Mar-2013
Publisher ELSEVIER SCIENCE INC
Journal Journal of molecular graphics & modelling 
Volume 40
Start page 91
End page 98
ISSN 1093-3263
DOI 10.1016/j.jmgm.2012.12.001
PubMed ID 23353584
Scopus ID 2-s2.0-84872801584
Web of science ID WOS:000316590700011

Attached Files

File Description SizeFormat Existing users please Login
البحث التاسع.pdf1.41 MBAdobe PDF    Request a copy
Recommend this item

Similar Items from Core Recommender Database

Google ScholarTM

Check

Citations 6 in pubmed
Citations 14 in scopus


Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.